Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report

Sarah J. Wu MD, PhD , Justin J. Kim GED , Yeying Huang BS , R. Taylor Durall BS , Simone Becker RN , Stephanie Canty CNP, MSN , Stefania Molinaro BS , Evan Pisick MD , Geoffrey I. Shapiro MD, PhD , Christopher A. French MD , Jia Luo MD
{"title":"Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report","authors":"Sarah J. Wu MD, PhD ,&nbsp;Justin J. Kim GED ,&nbsp;Yeying Huang BS ,&nbsp;R. Taylor Durall BS ,&nbsp;Simone Becker RN ,&nbsp;Stephanie Canty CNP, MSN ,&nbsp;Stefania Molinaro BS ,&nbsp;Evan Pisick MD ,&nbsp;Geoffrey I. Shapiro MD, PhD ,&nbsp;Christopher A. French MD ,&nbsp;Jia Luo MD","doi":"10.1016/j.jtocrr.2023.100625","DOIUrl":null,"url":null,"abstract":"<div><p>We present the first known case of a patient with <em>BRD2::NUTM1</em>-driven NUT carcinoma. A 59-year-old woman presented with poorly differentiated squamous cell lung cancer metastatic to the pleura. Eventually, a positive NUT immunohistochemistry, NUT fluorescence in situ hybridization, and RNA next-generation sequencing with a <em>BRD2::NUTM1</em> fusion led to the diagnosis of NUT carcinoma. She received multiple lines of chemotherapy with response and is still alive at 2 years postdiagnosis. This report expands on the known fusions in NUT carcinoma and highlights potential differences in patient prognosis on the basis of gene fusion partners.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364323001686/pdfft?md5=5196d7d17fc051b503b55fe9e7f25b4e&pid=1-s2.0-S2666364323001686-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364323001686","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We present the first known case of a patient with BRD2::NUTM1-driven NUT carcinoma. A 59-year-old woman presented with poorly differentiated squamous cell lung cancer metastatic to the pleura. Eventually, a positive NUT immunohistochemistry, NUT fluorescence in situ hybridization, and RNA next-generation sequencing with a BRD2::NUTM1 fusion led to the diagnosis of NUT carcinoma. She received multiple lines of chemotherapy with response and is still alive at 2 years postdiagnosis. This report expands on the known fusions in NUT carcinoma and highlights potential differences in patient prognosis on the basis of gene fusion partners.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
NUT癌中的新型BRD2::NUTM1融合,对化疗反应特殊:病例报告
我们介绍了第一例已知的BRD2::NUTM1驱动的NUT癌患者。一名 59 岁的女性患者因分化不良的鳞状细胞肺癌转移至胸膜而就诊。最终,经NUT免疫组化阳性、NUT荧光原位杂交和BRD2::NUTM1融合的RNA新一代测序,确诊为NUT癌。她接受了多线化疗,但均有反应,确诊后两年仍健在。本报告扩展了已知的 NUT 癌融合基因,并强调了根据基因融合伙伴的不同,患者预后可能存在的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
145
审稿时长
19 weeks
期刊最新文献
Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC Regarding: “Olloni A, et al. Heart and Lung Dose as Predictors of Overall Survival in Patients With Locally Advanced Lung Cancer. A National Multicenter Study” Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301) The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1